AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...

AstraZeneca PLC closed 22.80% short of its 52-week high of £133.88, which the company reached on September 3rd.

(Reuters) -AstraZeneca CEO Pascal Soriot is considering moving the company's stock market listing to the U.S., the Times ...

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

In a shock move, AstraZeneca has ditched a plan to invest £450 million ($558 million) in a new vaccine manufacturing plant in the UK, after the government reduced the offer on the table to ...

Review the current valuation for AstraZeneca PLC ADR (AZN:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.

Review the current AstraZeneca PLC ADR (AZN:XNAS) dividend yield and history to decide if AZN is the best investment for you.